7^th International Conference and Expo on Molecular & Cancer Biomarkers September 15-16, 2016 Berlin, Germany

A cancer biomarker is an element or procedure that indicates the presence of cancer in the body. A biomarker may be any molecule released by presence a tumor or a specific indication of the body to the presence of cancer. Cancer biomarkers are usually biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease. 

Biomarkers which are used for clinical purposes are called clinical biomarkers. Clinical biomarkers provide a vibrant and influential methodology to understanding the range of many diseases with uses in judgemental and analytic epidemiology, arbitrary clinical trials, screening for drugs or disease diagnosis and prognosis. Defined as changes in the constituents of cells or body fluids, these clinical biomarkers offer the means for standardized classification of a disease and risk factors, and the can extend the base information about the underlying pathogenesis of disease.

Biomarkers play a significant role in prognosis, diagnosis and treatment of cancers these days. There are many types of cancers which are hard to even diagnose. The latest designed biomarkers and their applications provide a great advantage in these cases.  

Biomarkers plan an important role in various neurological and cardiovascular diseases. The diseases which are incurable from ages are being offered a possible treatment and easy diagnosis with the help of advancements in biomarkers through different diagnostics and imaging technologies. 

Even though radiological sciences have long history in the medical field, Imaging Biomarkers have given it a new turn. In the modern day radiology, biomarkers have an undividable integral part which has become the major reason for the latest developments in this field. This biomarker conference places a special session to focus on this area of research.

Circulating biomarkers allow for the possibility of early, non-invasive detection of cancers. They also represent highly sensitive biomarkers of submissive disease and are capable of reflecting tumour affliction and cancer changing aspects. In the cancer biomarkers conferences, clinical, technical, and biological aspects of cell free biomarkers, and new technologies and techniques will be discussed. Special attention will be given to studies on clinical cases to further see the sights of the applications of these biomarkers and prospective of cell free biomarkers in disease diagnostics.

Cancer biomarkers have become an indispensable part of cancer patient care. With discovery efforts on-going, the next phase towards conversion will involve validation and verification of clinical value. This includes the steps needed to manage the new treatment model from treating clinical symptoms to targeting genomic pathways. Focus will be given to the use of circulating tumour material to follow patients peripherally, both with known metastatic disease and post-surgery. In these Molecular Biomarkers conferences a special importance is given to this field.

Biomarker discovery requires highly assured identification of a biomarker molecule with real-time quantitative information to indicate which proteins are altering to a statistically pertinent degree in response to disease. The discovery of molecular biomarkers has developed new strategies starting from the initial steps. In the first stage of biomarker discovery events, research depends upon mass spectrometry techniques to perform unbiased, semiquantitative analysis of differences between diseased and healthy states. Due to the high false positive rate, the slope of probable molecular biomarkers produced in the discovery stage are to be further verified through supplementary more targeted and quantitative mass spectrometry techniques, such as immunoaffinity peptide enrichment.

The probable Molecular Biomarkers identified in discovery section need to be validated by using larger sample sets casing a broad section of patient troops. To avoid a potential bottleneck associated with taking a large number of candidates to validation, a verification step is engaged to monitor potential molecular biomarkers to ensure that only the top quality biomarkers from the discovery phase are taken into the expensive validation stage. A high throughput workflow with a minimum of sample preparation is required in the verification stage which provides both high specificity and high sensitivity. Furthermore, the confirmation that a particular methodology is suitable to be used in the validation phase is given in verification stage. These advanced strategies can be sited at molecular biomarkers conference.

Biomarker testing is a group of tests that looks for the molecular signs of health so that doctors can plan the best care. Biomarker testing can also be called as genetic testing or molecular testing. Molecular biomarkers, a foundation of precision oncology, are very important in management of breast cancer, gastro-esophageal cancer and non-small cell lung cancer. Testing practices are intensely deliberated, influencing diagnostic quality and affecting pathologists, oncologists and patients.

The ability to look at a patient individually will provide a more precise diagnosis and specific treatment plan. The genetic information from individuals can then be used to effectively treat them, by finding the variations that can account for possible diseases. An individual’s genetic make-up also plays a large part in their extent of response to a certain treatment, and hence, having the knowledge of their genetic content can alter the type of treatment they receive. These approaches are intended to identify individualized patient benefits of therapies, minimize the risk of toxicity and reduce the cost of treatment.

A medical device, which is often an in vitro device and which offers information that is important for the safe and operative use of a respective drug or biological product is called a companion diagnostic. These devices help to determine whether a specific therapeutic product’s benefits to a patient will be of more importance that can overshadow any possible serious side effects or risks to treat a patient. These molecular biomarkers conferences invites the latest technologies and techniques to be brought into light.

In the biomarker pipeline, the technologies that will enable the use of biomarkers in drug discovery and development vary depending on the research stage. The second stage, biomarker validation and clinical assay development, depends upon extremely sensitive and specific high-throughput immunoassays. The single greatest challenge in discovering biomarkers with clinical utility is the sensitivity and specificity necessary to determine that a biomarker is truly positive for disease or toxicity, and can be used to detect deviations from normal. The molecular biomarkers conferences provide good exposure in drug discovery.

Molecular Imaging is a cross-discipline which is an intersection of in vivo imaging and molecular biology. It facilitates the picturing of the cellular function and the supplement of the molecular process in biological processes without disturbing the living organisms. The various fields of study the Molecular Imaging brings life into are diagnosis of diseases such as cancer, cardiovascular diseases and neurological disorders. This technique also donates to the improvisation of the treatment of various diseases and disorders by adjusting the pre-clinical and clinical tests of new drugs. The molecular dynamics meetings are also expected to have a major economic impact due to very prior and more precise diagnosis.

The study of cancer is called Oncology. An oncologist is a person who specializes in the area of oncology and treating cancer patients. An oncologist manages care and treatment once a person is diagnosed with cancer.

A case report is an elaborated report of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient usually recorded in medical field. Case reports might comprehend a demographic profile of the patient, but typically mention any unusual or unique occurrences. 

Self-knowledge is the key ingredient in successful entrepreneurship. Molecular Biomarkers conferences aim to bring together all existing and promising bio entrepreneurs to share capabilities and present new novelties and challenges in biomarker community. Over a million companies are started in the world each year, in which about 5–10 of them are classified into high technology companies. Whirling ideas into business ventures is complex and the opportunity appreciation step is critical in new project creation. This idea in the entrepreneur's perception of the association between the invention and final product is converted into a business prototype that describes how the venture generate revenue or provide an suitable yield to the prospective investors. Biological science is multifaceted and rapidly expanding and requires a expert knowledge to comprehend the value of the advances and its competitive situation in the industry. Even though scientists are stereotypically the founders of biotech companies, studies indicate that the most effective start-ups are founded by a team which often has two to three individuals with mixed backgrounds, considerable industry experience and a very strong market and product focus at establishment. This two day world-wide molecular and cancer biomarkers conferences will be a highly interactive forum that will bring experts in highly significant areas ranging from Biomarker discovery to latest diagnostics and Rx-Dx relationships.